Navigation Links
Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Date:6/22/2013

/ul>
  • Improvements in diastolic blood pressure (DBP) with empagliflozin versus placebo:
    • In patients with mild renal impairment, DBP decreased by 1.4 mmHg (p=0.006) and
      2.2 mmHg (p<0.001) for empagliflozin 10 mg and 25 mg, respectively, while it increased by 1.1 mmHg for placebo
    • In patients with moderate renal impairment, DBP decreased by 1.7 mmHg (p=0.020) for empagliflozin 25 mg and increased by 0.2 mmHg for placebo.1
  • The percentage of people with mild renal impairment who reported drug-related AEs at 52 weeks were 37.8 percent, empagliflozin 10 mg; 41.2 percent, empagliflozin 25 mg; and 32.6 percent, placebo. Drug-related AEs at 52 weeks in patients with moderate renal impairment were reported by 27.3 percent, empagliflozin 25 mg; and 24.1 percent, placebo. Observed AEs included hypoglycemia, events consistent with urinary tract infection, events consistent with genital infection, events consistent with volume depletion, and events consistent with bone fracture.

    About the study
    The 52-week randomized, double-blind, placebo-controlled trial investigated the safety and efficacy of empagliflozin as add-on to existing therapy in people with type 2 diabetes mellitus and renal impairment.1 Patients with mild renal impairment received empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Patients with moderate or severe renal impairment received empagliflozin 25 mg or placebo. The primary endpoint was change from baseline in HbA1c at week 24. Exploratory endpoints included changes from baseline in FPG, weight and BP at week 24.1

    About the Empagliflozin Phase III Clinical Trial Program
    Empagliflozin is being investigated in adults with T2D in a phase III clinical trial program that has enrolled more than 14,500 people. In total, this program comprises more than 10 multinational clinical trials, including a l
    '/>"/>

    SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
    2. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
    3. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
    4. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
    5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
    6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
    7. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
    8. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
    9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
    10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    11. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... Oct. 1, 2014  Dyadic International, Inc. ("Dyadic") ... and proprietary technology used to develop and produce ... chemicals, biopharmaceuticals, and industrial enzymes industries, today announced ... Abengoa Bioenergy for commercial scale production of Abengoa,s ... ethanol, developed under Abengoa,s license agreement with Dyadic. ...
    (Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
    (Date:10/1/2014)... ALTO, Calif. , Oct. 1, 2014  Varian ... that it will report results for the fourth quarter ... trading on Wednesday, October 22, 2014.  The news release ... interested parties at 2:00 p.m. PT.  The news release ... be available on the company website at: www.varian.com/investor ...
    Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
    ... March 29, 2011 Konica Minolta Sensing Americas, Inc. ... color, light and shape, announces the launch of its ... the pharmaceutical industry at the 2011 Interphex show March ... Center. (Photo: http://photos.prnewswire.com/prnh/20100714/NY35146 ) ...
    ... March 29, 2011 SinoFresh® HealthCare, Inc., (Pink Sheets: ... signed contracts with three high volume sales agencies. These ... boost to long term sales and distribution along the ... SinoFresh,s Antiseptic Homeopathic Nasal and Sinus Care Spray available ...
    Cached Medicine Technology:Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 2Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 3SinoFresh HealthCare Signs Three Sale Marketing Agreements 2SinoFresh HealthCare Signs Three Sale Marketing Agreements 3
    (Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
    (Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
    (Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
    (Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected as ... American Made Awards (MSAMAs), an annual competition in recognition ... fields of crafts, design, food and style. , ... the MSAMAs, which celebrates entrepreneurs and artisans who are ... and changing the way we shop, work and live,” ...
    (Date:10/1/2014)... Dr. Saj Jivraj, one of the world’s ... to Chennai, India, tomorrow to speak at the Indian ... , Dr. Jivraj is founder of the Anacapa Dental ... one of the world’s foremost prosthodontists, meaning he is ... speaking to the Indian Society of Oral Implantologists about ...
    Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
    ... device company publicly traded on the Tel-Aviv Stock Exchange (TASE: ... Journal of Human Hypertension . The advance online publication ... The study will also be published in the May issue ... of RESPeRATEthe only medical device cleared by the FDA and ...
    ... March 9 Surgical Information Systems (SIS) unveils SIS ... tissue lifecycle and provides the means for hospitals to ... tissues. The first tissue tracking solution to be ... manages tissue in a manner that enables hospitals to ...
    ... March 9 President Obama signed an ... human embryonic stem cell research, overturning limits on federal ... Charmaine Yoest, President & CEO of Americans United for ... of the past. Millions of dollars have been ...
    ... The Christopher & Dana Reeve Foundation joins millions ... previous restrictions on federal funding of human embryonic stem ... the Reeve Foundation, stated, "With a stroke of his ... of Americans and harnessed the power of the federal ...
    ... Delays and Unnecessary StaysCOLLEGE PARK, Md., March 9 ... H. Smith School of Business put a price tag on ... billion per year. The research, newly released from the Center ... to quantify the economic impact of a health care system ...
    ... YORK, Pa., March 9 The Danone Baby Nutrition ... bottle manufacturing plant in Zoetermeer, the Netherlands, as the ... is the equivalent of a supplier-of-the-year award and is ... at all levels -- during 2008," said Rafael Fernandez, ...
    Cached Medicine News:Health News:New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients 2Health News:SIS Trax Unveiled as First Fully Integrated Tissue Management Solution 2Health News:Americans United for Life: Obama Administration Stem Cell Policy an Anti-Life Waste of Tax Dollars 2Health News:Christopher & Dana Reeve Foundation Commends President Obama's Decision to Lift Federal Restrictions on Stem Cell Research 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 3Health News:Graham Packaging On-Site Plant in Zoetermeer Wins Top Performance Award From The Danone Baby Nutrition and Medical Nutrition Divisions 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: